STERIS plc

STE

IE00BFY8C754

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:01 2024-04-26 pm EDT			5-day change	1st Jan Change
203.9 ^USD	+1.17%		+2.20%	-7.25%

Apr. 19	Wolfe Research Adjusts STERIS Price Target to $235 From $245	MT
Apr. 11	Sector Update: Health Care Stocks Steady Pre-Bell Thursday	MT

STERIS plc Confirms Earnings Guidance for the Fiscal Year 2024

November 07, 2023 at 04:30 pm EST

STERIS plc confirmed earnings guidance for the fiscal year 2024. For the year the company expected revenue growth of 9% to 10% and constant currency organic revenue growth of 6% to 7%.

Latest news about STERIS plc

Wolfe Research Adjusts STERIS Price Target to $235 From $245	Apr. 19	MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
STERIS to Sell Dental Business to Peak Rock Capital for $787.5 Million in Equity Transaction	Apr. 11	MT
Peak Rock Capital LLC entered into a definitive agreement to acquire Dental segment of STERIS plc for $800 million.	Apr. 10	CI
Transcript : STERIS plc, Q3 2024 Earnings Call, Feb 08, 2024	Feb. 08
Steris beats third-quarter estimates on strong medical procedure demand	Feb. 07	RE
Steris Fiscal Q3 Earnings, Revenue Increase; Fiscal 2024 Guidance Revised	Feb. 07	MT
STERIS plc Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 07	CI
STERIS plc Revises Financial Guidance for the Fiscal Year 2024	Feb. 07	CI
MORNING BID AMERICAS-Global calm returns, regional banks rumble	Feb. 07	RE
Steris Keeps Quarterly Dividend at $0.52 a Share, Payable March 22 to Shareholders of Record Feb. 23	Jan. 30	MT
STERIS plc Announces Quarterly Interim Dividend, Payable on March 22, 2024	Jan. 30	CI
Morgan Stanley Cuts Price Target on STERIS to $215 From $225, Keeps Equalweight Rating	Dec. 04	MT
BD forecasts full-year profit below estimates on China headwinds	Nov. 09	RE
ANALYST RECOMMENDATIONS : Biogen, Conocophillips, Kellanova, Take Two, Tesla...	Nov. 09
Transcript : STERIS plc, Q2 2024 Earnings Call, Nov 08, 2023	Nov. 08
Steris' quarterly revenue beats estimates on strength in Healthcare segment	Nov. 07	RE
Steris Fiscal Q2 Adjusted Earnings, Revenue Rise; Fiscal 2024 Outlook Reaffirmed	Nov. 07	MT
Tranche Update on STERIS plc's Equity Buyback Plan announced on May 3, 2023.	Nov. 07	CI
STERIS plc Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
STERIS plc Confirms Earnings Guidance for the Fiscal Year 2024	Nov. 07	CI
MORNING BID AMERICAS-Some payback, but bonds hug gains on oil	Nov. 07	RE
STERIS plc Announces Quarterly Interim Dividend, Payable on December 21, 2023	23-10-31	CI
Piper Sandler Adjusts Price Target on STERIS to $215 From $220, Maintains Neutral Rating	23-10-27	MT
All hail the resilience of the US economy	23-10-26

STERIS plc is one of the world's leading providers of infection control solutions and procedural services. Net sales break down by activity as follows: - sales of infection control solutions (62.9%): including cleaning and sterilization chemicals, accessories for gastrointestinal procedures, washers, sterilizers and operating room equipment (including surgical tables, lighting and connectivity solutions). In addition, the group offers specialized healthcare services (sterilization services, instrument and endoscope repair and maintenance and customized process improvement consulting in acute care hospitals); - development of applied sterilization solutions (22.1%): contract development of sterilization modalities and laboratory testing services for more than 50 sterilization and laboratory facilities worldwide; - manufacturing of consumables and maintenance equipment (15%): dedicated to pharmaceutical manufacturers. Net sales by source of income are divided into sales of services (53.5%), sales of consumables (23.4%) and sales of equipment (23.1%). Net sales are distributed geographically as follows Ireland (2.3%), the United States (71.7%) and other (26%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-07 - Q4 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for STERIS plc

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

203.9 USD

Average target price

239.9 USD

Spread / Average Target

+17.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STERIS PLC	-7.25%	20.15B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution

STERIS plc

Equities

STE

IE00BFY8C754

Medical Equipment, Supplies & Distribution

STERIS plc Confirms Earnings Guidance for the Fiscal Year 2024

Latest news about STERIS plc

Chart STERIS plc

Company Profile

Income Statement Evolution

Ratings for STERIS plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution